Johnson & Johnson 13F Holdings · Q2 2026
Johnson & Johnson reported 15 securities worth $798.65M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: PTGX (37.59%), NBTX (26.55%), MGTX (11.23%). Among its top 25 positions this quarter: 1 new, 2 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PTGX | PROTAGONIST THERAPEUTICS INC | $300.2M | 37.59% | 2.4M | Hold |
| 2 | NBTX | NANOBIOTIX | $212.0M | 26.55% | 5.6M | Hold |
| 3 | MGTX | MEIRAGTX HLDGS PLC | $89.7M | 11.23% | 6.6M | Hold |
| 4 | RAPP | RAPPORT THERAPEUTICS INC | $74.4M | 9.31% | 1.8M | Hold |
| 5 | CTNM | CONTINEUM THERAPEUTICS INC | $32.4M | 4.06% | 2.0M | Hold |
| 6 | LEGN | LEGEND BIOTECH CORP | $23.5M | 2.95% | 814,586 | Hold |
| 7 | CVRX | CVRX INC | $20.7M | 2.59% | 4.0M | Hold |
| 8 | XNCR | XENCOR INC | $12.0M | 1.51% | 748,062 | Hold |
| 9 | CBRS | CEREBRAS SYSTEMS INC | $11.8M | 1.48% | 53,586 | New |
| 10 | FATE | FATE THERAPEUTICS INC | $9.1M | 1.14% | 3.4M | Hold |
| 11 | PRCT | PROCEPT BIOROBOTICS CORP | $8.1M | 1.01% | 357,939 | Hold |
| 12 | NMRA | NEUMORA THERAPEUTICS INC. | $3.1M | 0.39% | 1.8M | Hold |
| 13 | VOR | VOR BIOPHARMA INC | $989,206 | 0.12% | 53,732 | Hold |
| 14 | LAB | STANDARD BIOTOOLS INC | $256,655 | 0.03% | 311,967 | Hold |
| 15 | ACET | ADICET BIO INC | $196,811 | 0.02% | 22,779 | Hold |
| 16 | NNOX | Nano-X Imaging Ltd. | $0 | 0.00% | 0 | Exited |
| 17 | RLYB | Rallybio Corporation | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR